nouscom, Autore presso Nouscom

Nouscom is presenting at the TMB & Neoantigen Congress

Nouscom will present at the TMB & Neoantigen Congress from October 10-11, 2019 in London.

Nouscom demonstrates Preclinical Proof of Concept for Personalized Cancer Neoantigen Vaccine in combination with Immune Checkpoint Blockade to Eradicate Large Tumors

19th June 2019 – Article published in Nature Communications Nouscom, an immuno-oncology company developing off-the-shelf and personalized cancer neoantigen vaccines, announced today the [...]

IND for NOUS-209, an ‘off-the-shelf’ Neoantigen Cancer Vaccine, Cleared by FDA to Commence Clinical Development in MSI Solid Tumors

BASEL, Switzerland – 3rd June 2019: Nouscom, an immuno-oncology company developing off-the-shelf and personalized cancer neoantigen vaccines, announced today that its Investigational New Drug [...]

Sviluppo di una piattaforma per l’identificazione del mutanoma e la vaccinazione personalizzata in pazienti affetti da tumore – PRECIVAX

“Sviluppo di una piattaforma per l’identificazione del mutanoma e la vaccinazione personalizzata in pazienti affetti da tumore – PRECIVAX” “Development of a [...]

Dr. Marina Udier, COO of Nouscom, will give a talk about our company at the BaselArea.swiss Life Science Event on June 20, 2019 in Basel

The BaselArea.swiss Life Science event will have Dr. Marina Udier, COO of Nouscom, talking about the story of the company and sharing insights and learnings along the way.

Nouscom is presenting at the TMB & Neoantigen Congress

Nouscom demonstrates Preclinical Proof of Concept for Personalized Cancer Neoantigen Vaccine in combination with Immune Checkpoint Blockade to Eradicate Large Tumors

IND for NOUS-209, an ‘off-the-shelf’ Neoantigen Cancer Vaccine, Cleared by FDA to Commence Clinical Development in MSI Solid Tumors

Sviluppo di una piattaforma per l’identificazione del mutanoma e la vaccinazione personalizzata in pazienti affetti da tumore – PRECIVAX

Dr. Marina Udier, COO of Nouscom, will give a talk about our company at the BaselArea.swiss Life Science Event on June 20, 2019 in Basel

Nouscom will present at the NeoAg Summit 2018

Nouscom Strengthens Board of Directors with the Appointment of John F. McDonald as an Independent Director

Nouscom will present at the World Vaccine Congress Europe 2018

ProBioGen and Nouscom Sign License Agreement for ProBioGen’s Technology Platform

Immune Profiling of Premalignant Lesions in Patients With Lynch Syndrome